• 1. An aptasensor for detection of potassium ions based on RecJf exonuclease mediated signal amplification
  Bidou Wang,Xifeng Chen Analyst, 2014,139, 5695-5699
• 2. An amorphous carbon nitride/NiO/CoN-based composite: a highly efficient nonprecious electrode for supercapacitors and the oxygen evolution reaction?
  Huifang Yang,Haoran Guo,Peidong Fan,Xinpan Li,Wenlu Ren,Rui Song Nanoscale, 2020,12, 7024-7034
• 3. An asymmetric supercapacitor based on controllable WO3 nanorod bundle and alfalfa-derived porous carbon?
  Kanjun Sun,Fengting Hua,Shuzhen Cui,Yanrong Zhu,Hui Peng,Guofu Ma RSC Adv., 2021,11, 37631-37642
• 4. An assay for the enzyme N-acetyl-β-d-glucosaminidase (NAGase) based on electrochemical detection using screen-printed carbon electrodes (SPCEs)
  R. M. Pemberton,J. P. Hart,T. T. Mottram Analyst, 2001,126, 1866-1871
• 5. An aqueous ammonia sensor based on an inkjet-printed polyaniline nanoparticle-modified electrode
  Karl Crowley,Eimer O'Malley,Aoife Morrin,Malcolm R. Smyth,Anthony J. Killard Analyst, 2008,133, 391-399

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives Methylpyridines

Research Brief on (3-Methylpyridin-2-yl)methanol hydrochloride (CAS: 70580-08-4): Recent Advances and Applications

(3-Methylpyridin-2-yl)methanol hydrochloride (CAS: 70580-08-4) is a significant chemical intermediate in pharmaceutical synthesis, particularly in the development of novel therapeutic agents. Recent studies have highlighted its role as a key building block in the synthesis of biologically active compounds, including kinase inhibitors and antimicrobial agents. This research brief synthesizes the latest findings regarding this compound, focusing on its synthetic applications, pharmacological potential, and recent methodological advancements.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the compound's utility in synthesizing potent JAK3 kinase inhibitors. Researchers utilized (3-Methylpyridin-2-yl)methanol hydrochloride as a crucial intermediate in developing selective inhibitors with improved pharmacokinetic profiles. The study reported IC50 values in the low nanomolar range, suggesting promising therapeutic potential for autoimmune diseases.

In antimicrobial research, a recent ACS Infectious Diseases publication (2024) described novel derivatives synthesized from 70580-08-4 showing remarkable activity against drug-resistant Gram-positive bacteria. The structural flexibility of the (3-Methylpyridin-2-yl)methanol scaffold allowed for the development of compounds with minimum inhibitory concentrations (MICs) as low as 0.5 μg/mL against MRSA strains, while maintaining favorable cytotoxicity profiles in mammalian cell lines.

Methodological advancements in the synthesis and purification of 70580-08-4 have been reported in Organic Process Research & Development (2023). Researchers developed a novel continuous flow process that improved yield by 22% compared to traditional batch methods, while reducing solvent waste by 40%. This green chemistry approach significantly enhances the compound's accessibility for large-scale pharmaceutical applications.

Structural-activity relationship (SAR) studies published in Bioorganic & Medicinal Chemistry Letters (2024) have provided new insights into the compound's pharmacophore characteristics. X-ray crystallography data revealed that the hydrochloride salt form (70580-08-4) offers superior stability and solubility compared to the free base, particularly in aqueous formulations, making it preferable for drug development purposes.

Ongoing clinical trials (Phase I/II) listed in ClinicalTrials.gov indicate that derivatives of (3-Methylpyridin-2-yl)methanol hydrochloride are being evaluated as potential treatments for inflammatory bowel disease and certain hematological malignancies. Preliminary results suggest good tolerability and promising efficacy signals, though complete data analysis is pending.

Future research directions highlighted in recent review articles emphasize the need for further exploration of this scaffold in targeted drug delivery systems and as a component of PROTACs (Proteolysis Targeting Chimeras). The compound's structural features make it particularly suitable for these emerging therapeutic modalities, potentially opening new avenues in precision medicine.

• 38070-79-0(Pyridine-2,3-dimethanol)
• 63071-09-0((3-methylpyridin-2-yl)methanol)
• 22940-71-2((5-methylpyridin-2-yl)methanol)
• 848774-90-3(3,6-dimethyl-2-Pyridinemethanol)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)